Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNC116 in Refractory Systemic Lupus Erythematosus
NCT07748156Phase 1Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC116 in systemic lupus erythematosus (SLE), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Adverse Events at 3 months and Dose Limiting Toxicity at 28 days. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SNC116
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07748156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748156.